L. Machet

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

P. Joly, Maud Maho‐Vaillant, C. Prost‐Squarcioni et al. · The Lancet · 2017 · 596 citations

Medicine, Internal Medicine, Pharmacotherapy +9

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 389 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Florent Grange, M. Beylot‐Barry, Phillipe Courville et al. · Archives of Dermatology · 2007 · 262 citations

Medicine, Dermatology, Oncology +17

Blastic NK-Cell Lymphomas (Agranular CD4+CD56+ Hematodermic Neoplasms)

Tony Petrella, Martine Bagot, Rein Willemze et al. · American Journal of Clinical Pathology · 2005 · 232 citations

Medicine, Oncology, Pathology +15

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Brigitte Dréno, John F Thompson, B. Mark Smithers et al. · The Lancet Oncology · 2018 · 198 citations · Full text

Medicine, Immunology, Oncology +14